JPM: AbbVie pledges price increases below 10%

With drug pricing already a contentious topic, companies have been making promises to cap additional hikes.

By Suzanne Elvidge • Jan. 13, 2017

Bird Rock one step closer to acquisition by J&J

The approval of a Phase 1 trial for one of the small biopharma's drugs furthers the possibility of a takeover from Johnson & Johnson, which locked down acquisition rights earlier this year.

By Suzanne Elvidge • Jan. 12, 2017

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

JPM: Bresch calls out pricing transparency

The Mylan executive had a lot to say about the steps other companies are taking to rein in pricing. 

By Lisa LaMotta • Jan. 11, 2017

JPM: Coherus sticks to 2018 timeline for Humira biosimilar

The California-based biopharma says that it has a strategy that should bring its Humira biosimilar candidate to market next year.

By Judy Packer-Tursman • Jan. 11, 2017

Merck files Keytruda combo for lung cancer

This could be first approval of immuno-oncology chemotherapy combo in non-small cell lung cancer. 

By Suzanne Elvidge • Jan. 11, 2017

JPM: Saunders, Pops, others talk drug pricing

Industry executives and representatives gathered to discuss the complicated issue of drug pricing, failing to find a solution. 

By Lisa LaMotta • Jan. 10, 2017

Report: Oncology, profitable drugs move to market faster, patent exclusivity shrinking

A new report from QuintilesIMS finds certain groups of products are more likely to make it from research to markets and hold on to their patent exclusivity.

By Jacob Bell • Jan. 9, 2017

Judge hands Amgen major patent victory over PCSK9 rivals

A U.S. district court judge barred Sanofi and Regeneron's Praluent from markets, granting Amgen's request for a permanent injunction.

By Ned Pagliarulo • Jan. 6, 2017

Sanofi asked to pull vaccine ads in the Philippines

The country's Food and Drug Administration called on the French pharma to pull radio and television ads for its Dengue fever vaccine, Dengvaxia.

By Jacob Bell • Jan. 4, 2017

Biogen's SMA drug gets high price tag

Spinraza approval could kick off more pricing arguments as Biogen prices on the high end of expectations. 

By Suzanne Elvidge • Jan. 4, 2017

RedHill, Concordia team up to market IBS drug

Under terms of a new agreement, RedHill will gain some U.S. promotional rights to Concordia's Donnatal.

By Jacob Bell • Jan. 3, 2017

Threat grows for biologics makers as biosimilars take root

BioPharma Dive will be publishing several articles in the coming weeks comparing the dependence of some pharmas on revenue from best-selling drugs.

By Ned Pagliarulo • Dec. 29, 2016

FDA warns drugmakers on misleading marketing

Two companies were hit with warning letters last week for failing to disclose risks associated with their respective drugs.

By Ned Pagliarulo • Dec. 21, 2016

Novartis sells US rights to 3 COPD drugs

Sunovion Pharmaceuticals will take over U.S. commercialization, although Novartis will continue to manufacture the medicines. 

By Jacob Bell • Dec. 21, 2016

Bristol continues immuno-oncology push in deal with PsiOxus

The deal could be worth more than $930 million, and gives Bristol-Myers exclusive rights to a pre-clinical oncolytic virus therapy.

By Jacob Bell • Dec. 20, 2016

Pfizer's Chantix loses its black box warning

The big biopharma announced on Friday the FDA had agreed to remove the warning from its smoking cessation drug.

By Jacob Bell • Dec. 19, 2016

BIO President responds to QuintilesIMS pricing report

In a posting on his company's website, Jim Greenwood called the report an "important step in setting the record straight" with regard to increasing drug prices.

By Jacob Bell • Dec. 14, 2016

First charges come in generic price-fixing probe

Accusations levied against former Heritage execs are part of a sweeping investigation by the DOJ into the pricing and marketing of generic drugs in the U.S. 

By Ned Pagliarulo • Dec. 14, 2016

Sanofi, Celgene flagged for misleading DTC ads

Television commercials for Sanofi's Toujeo and Celgene's Otezla both ran afoul of the FDA for creating misleading impressions on safety. 

By Ned Pagliarulo • Dec. 14, 2016

Xcertia launched to improve mobile health apps

The new nonprofit will promote best practices, aiming to draw in stakeholders from across industry and academia.

By Suzanne Elvidge • Dec. 14, 2016

CVS Health unveils diabetes cost-control program

Several months after rival Express Scripts rolled out spending caps for diabetes drugs, CVS will offer cost savings to patients who improve control of their disease. 

By Lisa LaMotta • Dec. 14, 2016

Bristol-Myers hit with marketing fine for Abilify

Off-label promotion of the antidepressant landed the biopharma in hot water with the NY Attorney General. 

By Suzanne Elvidge • Dec. 12, 2016

Endo chops sales force after ditching pain drug

The Irish biopharma plans to pump the resources saved from the decision into its branded drug portfolio.

By Jacob Bell • Dec. 8, 2016

Pfizer hit with record fine in UK for drug price hike

A U.K. competition regulator fined Pfizer and Flynn Pharma about $113 million for sharply increasing the price of an epilepsy drug by as much as 2600%. 

By Ned Pagliarulo • Dec. 7, 2016

Report: Biosimilars, specialty drugs inversely impact drug spend

While specialty drugs can be pricey and are slated to take up a bigger chunk of drug spending, biosimilars could curb the amount stakeholders pay for some drugs.

By Jacob Bell • Dec. 7, 2016